天津發展(00882.HK):力生製藥天津南開區土地將被收儲 補償款2.5億元
格隆匯7月26日丨天津發展(00882.HK)發佈公吿,力生製藥(002393.SH)(作為轉讓方)擬與天津城達房屋(由天津市南開區人民政府指定作為受讓方)就該等土地房產的收儲訂立補償協議,補償款額為人民幣2.479億元,惟須待力生製藥股東於股東大會上批准後方可作實。
根據披露,因應天津市城市建設總體規劃,天津市南開區人民政府已決定按照相關法律及法規收儲現時由力生製藥持有的該等土地房產的土地使用權。因此,力生製藥擬與天津城達房屋就該潛在收儲事項訂立主補償協議及補充補償協議,惟須待力生製藥股東於股東大會上批准後方可作實。
該等土地房產由工業用途的土地及房屋組成,並位於天津市南開區黃河道491號,根據相關房產權證分為兩部分,前者土地面積為13,317.50平方米及建築面積為8,030.80平方米,以及後者土地面積為16,629.10平方米及建築面積為11,180.16平方米。於本公吿日期,力生製藥為該等土地房產的註冊及實益擁有人,並擁有該等土地房產的獨家使用權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.